goat polyclonal anti r d systems Search Results


94
Bio-Rad antibodies goat antirb
Antibodies Goat Antirb, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+r+d+systems/pm37174731-220-36-39?v=Bio-Rad
Average 94 stars, based on 1 article reviews
antibodies goat antirb - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology mouse antir b
Mouse Antir B, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+r+d+systems/pm18762229-38-14-17?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
mouse antir b - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology antind goat anti mouse ccr1
Figure 2. Deficiency of <t>CCR1</t> abrogates ECI301-augmented antitumor effects after RFA. CCR1−/−or CCR5−/−mice were inoculated with BNL cells and treated as described in the legend to Fig. 1. Non–RFA-treated tumor volumes were measured twice a week in CCR1−/−(A) and CCR5−/−(B) mice. Points, mean; bars, SE. *, P < 0.05; **, P < 0.01.
Antind Goat Anti Mouse Ccr1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+r+d+systems/10__1158_slash_0008___5472__can___10___0096-63-13-17?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
antind goat anti mouse ccr1 - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

N/A
Transcription Factor Goat Anti Rabbit HRP conjugate
  Buy from Supplier

Image Search Results


Figure 2. Deficiency of CCR1 abrogates ECI301-augmented antitumor effects after RFA. CCR1−/−or CCR5−/−mice were inoculated with BNL cells and treated as described in the legend to Fig. 1. Non–RFA-treated tumor volumes were measured twice a week in CCR1−/−(A) and CCR5−/−(B) mice. Points, mean; bars, SE. *, P < 0.05; **, P < 0.01.

Journal: Cancer Research

Article Title: Antitumor Effect after Radiofrequency Ablation of Murine Hepatoma Is Augmented by an Active Variant of CC Chemokine Ligand 3/Macrophage Inflammatory Protein-1α

doi: 10.1158/0008-5472.can-10-0096

Figure Lengend Snippet: Figure 2. Deficiency of CCR1 abrogates ECI301-augmented antitumor effects after RFA. CCR1−/−or CCR5−/−mice were inoculated with BNL cells and treated as described in the legend to Fig. 1. Non–RFA-treated tumor volumes were measured twice a week in CCR1−/−(A) and CCR5−/−(B) mice. Points, mean; bars, SE. *, P < 0.05; **, P < 0.01.

Article Snippet: After fixation with 4% paraformaldehyde/PBS, at sections were stained with the combinations of antind goat anti-mouse CCR1 (Santa Cruz Biotechnology), D8a and anti-CCR1, anti-F4/80 and anti-CCR1, phyhrin (PE)-conjugated hamster anti-CD11c (BD Bioes) and anti-CCR1, anti-F4/80 and goat anti-mouse (R&D Systems), and anti-F4/80 and goat anti-mouse antibodies (R&D).

Techniques:

Figure 3. ECI301 increases CCR1-expressing cells in peripheral blood. Peripheral blood sample was harvested 8 h after RFA. Mononuclear cells were separated and stained with the indicated antibodies as described in Materials and Methods. Columns, mean percentages of CCR1+, CCR1 +CD4+, CCR1+CD8+, CCR1+CD11c+, or CCR1+F4/80+ cells (n = 3); bars, SD. *, P < 0.05.

Journal: Cancer Research

Article Title: Antitumor Effect after Radiofrequency Ablation of Murine Hepatoma Is Augmented by an Active Variant of CC Chemokine Ligand 3/Macrophage Inflammatory Protein-1α

doi: 10.1158/0008-5472.can-10-0096

Figure Lengend Snippet: Figure 3. ECI301 increases CCR1-expressing cells in peripheral blood. Peripheral blood sample was harvested 8 h after RFA. Mononuclear cells were separated and stained with the indicated antibodies as described in Materials and Methods. Columns, mean percentages of CCR1+, CCR1 +CD4+, CCR1+CD8+, CCR1+CD11c+, or CCR1+F4/80+ cells (n = 3); bars, SD. *, P < 0.05.

Article Snippet: After fixation with 4% paraformaldehyde/PBS, at sections were stained with the combinations of antind goat anti-mouse CCR1 (Santa Cruz Biotechnology), D8a and anti-CCR1, anti-F4/80 and anti-CCR1, phyhrin (PE)-conjugated hamster anti-CD11c (BD Bioes) and anti-CCR1, anti-F4/80 and goat anti-mouse (R&D Systems), and anti-F4/80 and goat anti-mouse antibodies (R&D).

Techniques: Expressing, Staining

Figure 6. ECI301 augments tumor-specific immune responses after RFA. A, non–RFA-treated tumors were removed from WT mice on day 3 after RFA, and immunohistochemical analysis was done using anti-CD4 or anti-CD8a antibodies. Representative results from three individual animals in each group. Original magnification, ×400. Bar, 50 μm. B, the numbers of CD4+ or CD8+ cells were counted. Cell density was determined in 10 randomly chosen tumor areas at 400-fold magnification. Columns, mean (n = 5); bars, SE. **, P < 0.01. C, BALB/c-nu/nu mice (left) and BALB/c-WT mice (right) were inoculated with BNL cells and treated as described in the legend to Fig. 1. In the RFA + ECI301 + clodronate liposome (CL) group, the mice were injected with 200 μL of CL to deplete monocytes/macrophages as described in Materials and Methods. Non–RFA-treated tumor volumes were measured twice a week. Points, mean; bars, SE. D, spleens from WT, CCR1−/−, or CCR5−/−mice were harvested on day 21 after RFA, and mononuclear cells were separated from the spleens for ELISPOT assay as described in Materials and Methods. The number of specific spots was determined by subtracting the number of spots in wells without lysates from the number of spots in wells with tumor lysates. Columns, mean (n = 3); bars, SE. *, P < 0.05; **, P < 0.01, compared with untreated WT mice.

Journal: Cancer Research

Article Title: Antitumor Effect after Radiofrequency Ablation of Murine Hepatoma Is Augmented by an Active Variant of CC Chemokine Ligand 3/Macrophage Inflammatory Protein-1α

doi: 10.1158/0008-5472.can-10-0096

Figure Lengend Snippet: Figure 6. ECI301 augments tumor-specific immune responses after RFA. A, non–RFA-treated tumors were removed from WT mice on day 3 after RFA, and immunohistochemical analysis was done using anti-CD4 or anti-CD8a antibodies. Representative results from three individual animals in each group. Original magnification, ×400. Bar, 50 μm. B, the numbers of CD4+ or CD8+ cells were counted. Cell density was determined in 10 randomly chosen tumor areas at 400-fold magnification. Columns, mean (n = 5); bars, SE. **, P < 0.01. C, BALB/c-nu/nu mice (left) and BALB/c-WT mice (right) were inoculated with BNL cells and treated as described in the legend to Fig. 1. In the RFA + ECI301 + clodronate liposome (CL) group, the mice were injected with 200 μL of CL to deplete monocytes/macrophages as described in Materials and Methods. Non–RFA-treated tumor volumes were measured twice a week. Points, mean; bars, SE. D, spleens from WT, CCR1−/−, or CCR5−/−mice were harvested on day 21 after RFA, and mononuclear cells were separated from the spleens for ELISPOT assay as described in Materials and Methods. The number of specific spots was determined by subtracting the number of spots in wells without lysates from the number of spots in wells with tumor lysates. Columns, mean (n = 3); bars, SE. *, P < 0.05; **, P < 0.01, compared with untreated WT mice.

Article Snippet: After fixation with 4% paraformaldehyde/PBS, at sections were stained with the combinations of antind goat anti-mouse CCR1 (Santa Cruz Biotechnology), D8a and anti-CCR1, anti-F4/80 and anti-CCR1, phyhrin (PE)-conjugated hamster anti-CD11c (BD Bioes) and anti-CCR1, anti-F4/80 and goat anti-mouse (R&D Systems), and anti-F4/80 and goat anti-mouse antibodies (R&D).

Techniques: Immunohistochemical staining, Injection, Enzyme-linked Immunospot